I joined Oxford in October 2008 as Head of the Nuffield Department of Surgery, Nuffield Professor of Surgery, Professor of Urology and Honorary Consultant Urological Surgeon at the Oxford Radcliffe Hospitals as well as Fellow of Balliol College. I spent the past 10 years as founding Chair of Urology and was Director of the Division of Clinical Sciences, then Head of Oncology at the University of Sheffield. I trained in Surgery and Urology at Liverpool, Sheffield and Newcastle.
I have authored over 200 peer-reviewed articles, and raised to date over £40m in peer-reviewed grants.
- British Association of Urological Surgeons
- British Medical Association
- European Association of Urology
- American Urological Association
- Association of Academic European Urologists
- Deutsche Gesellschaft für Urologie (German Urological Society)
MBChB, LRCSPEd, LRCSEd, LRCPSGlasg, FRCSEd, MD, FRCSEd(Urol), MA (Oxon), FRCS, FMedSci.
Head of Department
- Nuffield Professor of Surgery
- Professor of Urology
- SITU Co-Director
My research focuses on management of urological malignancies, in particular prostate and bladder cancer.
Each year about 10,000 people in the UK are diagnosed with bladder cancer and about 40,000 men are diagnosed with prostate cancer, with prostate cancer being the the most common cancer in men.
My laboratory interest is the mechanisms of invasion/metastasis in prostate cancer and the interaction between primary prostate cancer cells and the bone microenvironment, as well as epigenetics of bladder cancer.
My clinical research interest is to provide evidence of treatment effectiveness in prostate cancer through large randomized controlled trials.
I am the Chief Investigator of many studies including the ProtecT (Prostate testing for cancer and Treatment) study of case-finding and randomised controlled trial of treatment effectiveness in prostate cancer - the largest of its kind worldwide. I am also establishing various multidisciplinary research platforms at Oxford and introducing, with colleagues, a new centre for evaluation of minimally invasive technology including robotic surgery.
- 1995 AUA/EAU Academic Exchange Fellowship
- 1996 EAU Crystal Matula Award
- 2001 Golden Telescope award, BAUS
- 2002 NHS ‘B’ Merit Award
- 2007 Fellow of the Academy of Medical Sciences
- 2007 NHS ‘Silver’ Award – ACCEA
- 2010 NIHR Senior Investigator Award
- 2012 St Peter’s Medal, BAUS
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.
Catto JWF. et al, (2010), Eur Urol, 57, 398 - 406
Multiple loci on 8q24 associated with prostate cancer susceptibility.
Al Olama AA. et al, (2009), Nat Genet, 41, 1058 - 1060
Distinct microRNA alterations characterize high- and low-grade bladder cancer.
Catto JWF. et al, (2009), Cancer Res, 69, 8472 - 8481
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Eeles RA. et al, (2009), Nat Genet, 41, 1116 - 1121
Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone.
Cross NA. et al, (2008), Prostate, 68, 1707 - 1714
Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
Sathianathen NJ. et al, (2020), Eur Urol
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.
Harrison S. et al, (2020), Cancer Causes Control, 31, 431 - 449
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Neal DE. et al, (2020), Eur Urol, 77, 320 - 330
Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit- The "Fry-Turnbull" Effect.
Lovegrove CE. et al, (2020), BJU Int
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
Bryant RJ. et al, (2020), BJU Int